Posts tagged ‘BIIB’
NYSE Euronext Talks About ‘Flash’ Orders, High-Frequency Trading and Co-Location
Its all right here
http://exchanges.nyse.com/archives/2009/07/talks.php
TiVo initiated with a Buy at Lazard Capital
Usec (USU) downgraded to Hold from Buy at Jefferies
After the DOE rejected its application for a loan guarantee for the American Centrifuge Project. The firm lowered its target on shares to $3.25
Pre Market trading
Northrop Grumman (NYSE:NOC) Northrop Grumman and the U.S. Air Force have developed a new radar system and have successfully demonstrated that the new radar developed for the B-2 stealth bomber can fulfill the performance requirements for its required missions, both conventional and strategic.
Suntech, China Huadian (NYSE:STP) sign agreement to develop 500MW of solar projects
Suntech Power Holdings announced that Suntech has recently entered into a strategic agreement with China Huadian New Energy Development Co., or HNE, to develop a total of 500MW of utility-scale and commercial roof-top solar projects in China’s sun rich western provinces, Jiangsu province and Shanghai over the next three years. Under the agreement, HNE will be responsible for the project investment and development of solar projects and Suntech will be responsible for supplying crystalline silicon solar modules, system design and technical support.
Wells Fargo EPS above expectations
Onyx Pharmaceuticals (ONXX) announced that their first cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo.
PIPE REPORT July 21, 2009
PIPE Volume Rose in 2nd Quarter, Compared With First
Posted July 21, 2009 12:00PM PST
The second quarter saw a promising increase in PIPE activity, as U.S.-listed companies raised $12.9 billion, or 63% more capital than they did in the first quarter, according to PrivateRaise, the data service of DealFlow Media. The number of deals rose 32% over the first quarter.
Major players in the PIPE market in the first half of the year included Iroquois Capital and Downsview Capital, the only fund managers to invest in more than 10 offerings; and Rodman & Renshaw, which placed 27 PIPEs, three times the number of placements by Lazard, the second most active placement agent. Investors who brought the most cash to the PIPE market were Berkshire Hathaway, which invested $3 billion in a private placement; Aabar Investments PJSC, with $2.6 billion; and Kuwait Investment Authority, with $1 billion. The companies that raised the most capital included four Dow Chemical, with $4 billion; BlackRock, Inc., with $2.8 billion; Daimler AG, with $2.5 billion; and ArcelorMittal, with $1.7 billion.
Data from the first half shows that PIPE financing activity has not returned to levels prevailing before the credit crunch of late 2008 and fickle securities markets depressed most forms of financing. The first half of 2009 saw a 44% drop in deal volume, compared with the year earlier period, and a 68% decline in total investment.
The third and fourth quarters could bring a further rebound towards last year’s numbers. In addition to increased deal flow, second quarter numbers reflect a growing trend in registered shelf offerings or “registered directs.” Companies raised $967.7 million in 57 registered direct offerings last quarter, compared to $417.9 million in 25 first quarter deals. While registered directs accounted for only about 7% of capital raised in the second quarter, the number of shelf statements filed in anticipation of future raises more than doubled from the same quarter last year. The 250 shelf statements filed in the second quarter of this year could be used to raise as much as $39 billion. As much as $72 billion could be raised from shelf statements filed during the entire first half of the year.
Even at the current level of activity they represent a fraction of the total PIPE market, and are not a viable option for the majority of emerging growth companies that remain ineligible for S-3 registration and must rely on the traditional PIPE market for equity capital.
HGSI Up $7.00 at ther open Trade of the day
Human Genome news on Phase III
Human Genome Sciences (HGSI) anounced that BENLYSTA met the primary endpoint in BLISS-52, the first of two Phase 3 trials. In the placebo-controlled BLISS-52 study, the results showed that BENLYSTA response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.
SocialVibe